Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species

By Kalgutkar A. S.   Choo E.   Taylor T. J.   Marfat A.  

Xenobiotica, Vol. 34, Iss. 8, 2004-08 ,pp. : 755-770

Informa Healthcare

Access to resources Recommend Favorite

Disposition of GDC-0879, a B-RAF kinase inhibitor in preclinical species

By Choo E. F.   Driscoll J. P.   Feng J.   Liederer B.   Plise E.   Randolph N.   Shin Y.   Wong S.   Ran Y.  

Xenobiotica, Vol. 39, Iss. 9, 2009-09 ,pp. : 700-709

Informa Healthcare

Access to resources Recommend Favorite

Preclinical Antitumor Activity of Thiarabine in Human Leukemia and Lymphoma Xenograft Models

By Waud William R.   Gilbert Karen S.   Secrist John A.  

Nucleosides, Nucleotides & Nucleic Acids, Vol. 31, Iss. 9, 2012-09 ,pp. : 647-660

Taylor & Francis Ltd

Access to resources Recommend Favorite

Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human

By Salphati Laurent   Pang Jodie   Plise Emile G.   Chou Bilin   Halladay Jason S.   Olivero Alan G.   Rudewicz Patrick J.   Tian Qingping   Wong Susan   Zhang Xiaolin  

Xenobiotica, Vol. 41, Iss. 12, 2011-12 ,pp. : 1088-1099

Informa Healthcare

Access to resources Recommend Favorite

Preclinical evaluation of biomarkers for response monitoring to the MET inhibitor BAY-853474

By Klotz Monika   Schmid Elke   Steiner-Hahn Kirsten   Rose Tanja   Laube Jenny   Roese Lars   Henderson David   Krahn Thomas   von Ahsen Oliver  

Biomarkers, Vol. 17, Iss. 4, 2012-06 ,pp. : 325-335

Informa Healthcare

Access to resources Recommend Favorite